- Conditions
- Pancreatic Fistula, Distal Pancreatectomy Complications, Falciform Patch Pancreatic Closure, Fibrin Glue Pancreatic Closure
- Interventions
- Falciform patch and fibrin glue application, standard pancreatic closure
- Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 7,404
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth
- Interventions
- 0.12% CHX and Essential Oil mouthrinse, 2.6% EDTA and 0.2% EDTA mouth rinse
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 16 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cellulitis, Abscess, Drain Abscess, Impetigo, Skin Infection, Antibiotic Duration, Behavioral Economics
- Interventions
- Default Duration order Panel
- Behavioral
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Months to 99 Years
- Enrollment
- 1,634 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 2
- States / cities
- Berkeley, California • San Francisco, California
- Conditions
- Shoulder Pain, Chronic Pain, Musculoskeletal Injury
- Interventions
- Dry Needling, Sham Dry Needling
- Device · Other
- Lead sponsor
- Army-Baylor University Doctoral Program in Physical Therapy
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Exercise Rehab
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ischemic Stroke
- Interventions
- argatroban
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more
- Conditions
- Malignant Melanoma
- Interventions
- Atezolizumab, Cobimetinib, Vemurafenib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
- Conditions
- Cancer
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Follow-Up
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
- Biological · Drug · Other + 2 more
- Lead sponsor
- John Hays
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
- Conditions
- Colon Ischemia, Aortic Aneurysm
- Interventions
- Reestablish colon blood flow
- Procedure
- Lead sponsor
- Spectros Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Davis, California • Palo Alto, California
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, pharmacological study, laboratory biomarker analysis
- Biological · Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Burn Scar, Scar
- Interventions
- Punch biopsy, non-invasive photography, assessments, and measurements
- Other
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 91
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Limited Dorsiflexion, Limited Ankle Range of Motion
- Interventions
- Dry Needling, Stretching
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pain
- Interventions
- Botulinum Toxin A, Placebo - Saline
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Breast Cancer
- Interventions
- celecoxib 400 mg BID
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Breast Cancer
- Interventions
- Conjugated Linoleic Acid (CLA)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Tumor Infiltrating Lymphocyte, CD8-PET, Advanced Melanoma
- Interventions
- Crefmirlimb, PET/CT imaging
- Drug · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Soft Tissue Sarcoma
- Interventions
- Autologous total tumor mRNA loaded DOTAP liposome vaccine
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida